.jpg)
Founded in 1993, Fukang Group is primarily engaged in the R&D, production, and sales of over 80 products across six major sectors, including FDFs, APIs, thermosensitive new materials and so on. Fukang Group comprises nine subsidiaries, including Fukang Pharmaceutical Co., Ltd, Ruikang specialty Chemicals Co., Ltd, Yongkang Chemical Industry Co., Ltd, Bokang Pharmaceutical Co.,Ltd, and Inner Mongolia Xinhao Pharmaceutical Technology Co.,Ltd, and has become a key supplier to more than 20 of the world's top pharmaceutical companies.
Fukang Group achieved sales revenue of approximately $1 billion In 2024 and aims to reach a sales target of $1.5 billion by 2030. The group has passed U.S. FDA certification(5 times), EU certification(5 times), WHO certification(2 times), Japan PMDA certification(2 times), Australia TGA certification(2 times), Brazil ANVISA certification(1 time), and Mexico COFEPRIS certification(1 time), among other international quality certifications. Its products are distributed across 27 provinces in China and exported to over 80 countries and regions, including the United States, Canada, Russia, France, Spain, Germany, the UK, Poland, the Czech Republic, Italy, Japan, Indonesia, Malaysia, Mexico, and Brazil.
The leading products—Metformin Hydrochloride, Trimethoprim, Omeprazole, Clozapine, Phloroglucinol, and FB2C—rank first globally in production and sales volume, each holding over 70% of the domestic market share. Other products—Sulfamethoxazole, Clozapine, and Esomeprazole Magnesium—also rank first in China in production and sales volume. Nineteen formulation products, including Metformin Hydrochloride Extended-release Tablets, Pioglitazone and Metformin Tablets, Phloroglucinol Injection, Pantoprazole Sodium Enteric-coated Tablets, and Compound Sulfamethoxazole Tablets, have been launched and are commercially available. The Group possesses production capabilities for various dosage forms, such as injections, lyophilized powder injections, tablets, granules, and capsules, along with supporting APIs. It has established six complete and well-defined industrial chains, with metformin as a representative example.
Fukang Group has been recognized among "China's Top 100 Pharmaceutical Enterprises", "China's Top 100 Internationalized Pharmaceutical Enterprises", "Shandong Province's Top 10 Industrial Cluster Leading Enterprises" and "Weifang's Top 50 Tax Contributors". It has also received honors such as National High-Tech Enterprise, National Intellectual Property Advantage Enterprise, Shandong Province Key Enterprise for High-Level Talent Recruitment, and Weifang Outstanding Contribution Enterprise.